Profile picture

Doctor Carlos Escobar Cervantes

La Paz University Hospital, Madrid (Spain)
Follow
Biography
MD graduate at the Universidad Autonoma de Madrid. PhD grade at the Universidad de Alcalá; Doctoral Thesis qualification: A cum laude, unanimously. Specialist in Cardiology. Consultant cardiologist at Hospital La Paz (Madrid). Past President of the Clinical Cardiology group of the Spanish Society of Cardiology. Past-member of the Executive Committee of the Castilian Society of Cardiology. Member of the European Society of Cardiology (ESC). Member of the Cardiovascular Pharmacology and Drug Therapy Working Group of ESC. Referee of several national and international peer-review journals. Participation in several clinical trials and investigation projects in the fields of hypertension, heart failure, atrial fibrillation, acute coronary syndrome, and cardiometabolic disease. Over 250 papers published in national and international peer-review journals and over 40 chapters in Cardiology textbooks.
Logo ESC

Contributor content

New tools in cardiovascular risk assessment
Presentation
New tools in cardiovascular risk assessment
Not all drugs are made the same: from pharmacology to clinical efficacy
Presentation
Not all drugs are made the same: from pharmacology to clinical efficacy
Panel discussion and Q&A
Presentation
Panel discussion and Q&A
Could combination therapy become the first step to achieving LDL-C goals in high- and very high-risk patients?
Presentation
Could combination therapy become the first step to achieving LDL-C goals in high- and very high-risk patients?
Stroke and bleed related deaths in newly diagnosed atrial fibrillation patients: insights from the GARFIELD-AF registry
Presentation
Stroke and bleed related deaths in newly diagnosed atrial fibrillation patients: insights from the GARFIELD-AF registry
Potential low-density lipoprotein cholesterol, cardiovascular risk and costs reduction with evolocumab: a simulation in patients with a recent myocardial infarction in Spain
Presentation
Potential low-density lipoprotein cholesterol, cardiovascular risk and costs reduction with evolocumab: a simulation in patients with a recent myocardial infarction in Spain
Resource utilization and costs associated with achieved LDL-C levels in patients following a myocardial infarction treated with lipid-lowering therapies in Spain
Presentation
Resource utilization and costs associated with achieved LDL-C levels in patients following a myocardial infarction treated with lipid-lowering therapies in Spain
Pulmonary vein isolation by high-power short-duration radiofrequency applications: short term efficacy and safety in patients with atrial fibrillation
Presentation
Pulmonary vein isolation by high-power short-duration radiofrequency applications: short term efficacy and safety in patients with atrial fibrillation
Anticoagulation and CHA2DS2-VASc score of 1 - CONTRA
Presentation
Anticoagulation and CHA2DS2-VASc score of 1 - CONTRA

ESC 365 is supported by